ClinicalTrials.gg
CompletedNCT05027308Updated May 16, 2024Results posted

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Takeda. Completed at 6 sites in Japan. Open to participants aged 4 Months and older. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
4 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
20th of 20
3 · median 20
Started
2022
the only one that year
Phase 3
16 of 20
none open now
Registered
18th of 20
by date
Lead sponsor
3 of 20
Takeda

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 20th largest by enrollment, is the only one that started in 2022, is one of 16 in phase 3, and was the 18th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 4 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The main aims of the study are to check for side effects from teduglutide.

Participants will receive a daily injection of teduglutide just under the skin (subcutaneous) for 24 weeks. Then they are followed up for another 4 weeks. Participants may be able to repeat this treatment if they meet specific criteria. The study doctors will check for side effects from teduglutide until it becomes commercially available. The maximum duration of treatment is approximately 51.3 weeks.

Read the detailed description

A study of teduglutide in Japanese children with short bowel syndrome aged 4 months or older.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
4 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female pediatric patient of corrected gestational age 4 months or older.
  2. Body weight at the time of screening and baseline visits of at least 5 kg and \<10 kg for participants with normal renal function or mild renal impairment (estimated >=50 mL/min/1.73 m\^2), OR at least 10 kg and \<20 kg for participants with moderate or greater renal impairment (estimated glomerular filtration rate \<50 mL/min/1.73 m\^2).
  3. Diagnosis of short bowel syndrome (SBS) with intestinal failure, defined as dependence on PS to provide at least 30% of fluid or caloric needs.
  4. Participants to have stable PS for at least 1 month prior to screening as assessed by the investigator. Stable PS is defined as inability to significantly reduce parenteral nutrition/intravenous fluid (PN/IV) support, usually associated with minimal or no advance in enteral feeds (ie, 10% or less change in PN or advance in feeds), assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. A parent/guardian who is not capable of understanding or not willing to adhere to the study visit schedule and other protocol requirements.
  2. intestinal obstruction, active or recurrent pancreatic or biliary disease, or dysmotility that prevents the advancement of enteral intake.
  3. Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, etc.
  4. Severe, known dysmotility syndrome, such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility, that is the primary contributing factor to feeding intolerance and inability to reduce PS, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding.
  5. Major gastrointestinal (GI) surgical intervention including significant intestinal resection or bowel lengthening procedure within 3 months prior to screening (insertion of feeding tube, anastomotic ulcer repair, minor intestinal resections =\<10 cm and endoscopic procedures are allowed).
  6. Cardiac disease that makes the patient vulnerable to changes in fluid status.
  7. History of cancer or known cancer predisposition syndrome, such as juvenile polyposis or Beckwith-Wiedemann syndrome, or first degree relative with early onset of GI cancer (including hepatobiliary and pancreatic cancer).
  8. Concurrent treatment with glucagon-like peptide-2 (GLP-2), human growth hormone, or analogs of these hormones within 6 months prior to the screening visit, or concurrent treatment with octreotide, or GLP-1 analogs within 30 days prior to the screening visit.
  9. Concurrent treatment with biological therapy (eg, anti-tumor necrosis factor [anti-TNF]) for active Crohn's disease within 6 months prior to the screening visit.
  10. Participation in a clinical study using an experimental drug (other than glutamine or omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to the screening visit and for the duration of the study.
  11. Known or suspected intolerance or to the study drug, closely related compounds, or any of the stated ingredients.
  12. Signs of active, severe, or unstable clinically significant hepatic impairment during the screening period as meeting at least 2 of any of the following parameters:

    1. >1.5 not corrected with parenteral vitamin K
    2. count \<100×10\^3/mcrL due to portal hypertension
    3. Presence of clinically significant gastric or esophageal varices
    4. Cirrhosis
    5. Persistent cholestasis defined as conjugated >4 mg/dL (>68 mcr mol/L) over a 2-week period during screening
    6. Total bilirubin >=2x (ULN)
    7. (AST) >=3x ULN
    8. Alanine aminotransferase (ALT) >=3x ULN
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Teduglutide 0.05 milligram per kilogram (mg/kg)

    Participants will receive teduglutide 0.05 milligram per kilogram \[mg/kg\] (0.025 mg/kg for participants with moderate or greater renal impairment) subcutaneous \[SC\] injection once daily in a 28-week treatment cycle consisting of a 24-week treatment period followed by a 4-week no treatment follow-up period for a maximum of 3 cycles.

    Drug: Teduglutide

Interventions

  • Teduglutide 0.05 mg/kg SC injection

    Also known as: TAK-633

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.

    Time frame: From first dose of study drug until follow-up visit (4 weeks after end of treatment [EOT]/end of termination [ET] {up to 47.3-51.3 weeks})

  2. Number of Participants With Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly /birth defect, is the other important medical event.

    Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

  3. Number of Participants With Adverse Events of Special Interest (AESIs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AESI, whether serious or non-serious, is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate.

    Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

  4. Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event

    Vital signs include systolic and diastolic blood pressure, heart rate and body temperature.

    Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

  5. Change From Baseline in Body Weight Z-Score at EOT

    A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for age Z-score below -2 indicates underweight.

    Time frame: Baseline, EOT (up to 47.3-51.3 weeks)

  6. Change From Baseline in Height Z-Score at EOT

    A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a height for age Z-score below -2 indicates stunted.

    Time frame: Baseline, EOT (up to 47.3-51.3 weeks)

  7. Change From Baseline in Head Circumference Z-Score at EOT

    A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to the Food and Nutrition Technical Assistance (FANTA) Guide to Anthropometry used for assessment of this outcome measure, a head circumference for age Z-score below -2 indicates small head circumference.

    Time frame: Baseline, EOT (up to 47.3-51.3 weeks)

  8. Change From Baseline in Weight-for-Length Z-Score at EOT

    A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for length Z-score below -2 indicates wasted (recent and severe weight loss).

    Time frame: Baseline, EOT (up to 47.3-51.3 weeks)

  9. Number of Participants With Any Laboratory Safety Finding Reported as an Adverse Event

    Laboratory safety parameters included biochemistry, hematology, and urinalysis.

    Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

  10. Number of Participants With a Change in Urine Output Reported as an Adverse Event

    Urine and stool output was recorded and calculated in the output diary over a 48-hour period of parenteral support (PS) and enteral nutrition (EN) stability before every site visit and within 1 week of implementing a change in the PS prescription.

    Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

  11. Number of Participants With a Change in Stool Output Reported as an Adverse Event

    Urine and stool output was recorded and calculated in the output diary over a 48-hour period of PS and EN stability before every site visit and within 1 week of implementing a change in the PS prescription.

    Time frame: From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])

Secondary outcomes

  1. Change From Baseline in PS Volume

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period. An end of treatment (EOT) was defined as the last determination of endpoint of the last cycle.

    Time frame: Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2: Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]

  2. Percent Change From Baseline in PS Volume

    Percent change from baseline in PS volume was calculated as follows; (PS volume at each point \[Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT\] - PS volume at baseline)/ PS volume at baseline \*100 (percent). PS (parenteral nutrition or intravenous fluids) was to be considered for managing nutritional support in terms of volume and calories during the treatment period. An EOT was defined as the last determination of endpoint of the last cycle.

    Time frame: Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]

  3. Number of Participants Who Demonstrate at Least 20 Percent (%) Reduction From Baseline in PS Volume

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period. An EOT was defined as the last determination of endpoint of the last cycle.

    Time frame: Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]

  4. Number of Participants Who Achieved Enteral Autonomy

    Achieving enteral autonomy is defined as complete weaning off PS. PS (parenteral nutrition or intravenous fluids) was to be considered for managing nutritional support in terms of volume and calories during the treatment period.

    Time frame: Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]

  5. Change From Baseline in Number of Days Per Week of PS Usage at EOT

    PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period.

    Time frame: Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT, and overall EOT (for 47.3-51.3 weeks) [cycle length=28 weeks]

07

Results

Posted May 16, 2024

Participant flow

Three participants took part in the study at six investigative sites in Japan from 4 January 2022 to 27 September 2023.

Participant flow — Overall Study
MilestoneTeduglutide
Started3
Completed3
Not completed0

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened, or intensity increased after receiving the investigational product.

Time frame:
From first dose of study drug until follow-up visit (4 weeks after end of treatment [EOT]/end of termination [ET] {up to 47.3-51.3 weeks})
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTeduglutide
Number of Participants With Treatment-emergent Adverse Events (TEAEs)3
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly /birth defect, is the other important medical event.

Time frame:
From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsTeduglutide
Number of Participants With Serious Adverse Events (SAEs)3
PrimaryNumber of Participants With Adverse Events of Special Interest (AESIs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AESI, whether serious or non-serious, is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor may be appropriate.

Time frame:
From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESIs)
ParticipantsTeduglutide
Number of Participants With Adverse Events of Special Interest (AESIs)0
PrimaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event

Vital signs include systolic and diastolic blood pressure, heart rate and body temperature.

Time frame:
From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event
ParticipantsTeduglutide
Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event0
PrimaryChange From Baseline in Body Weight Z-Score at EOT

A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for age Z-score below -2 indicates underweight.

Time frame:
Baseline, EOT (up to 47.3-51.3 weeks)
Reported as:
Mean · Z score
Change From Baseline in Body Weight Z-Score at EOT
Z scoreTeduglutide
Change From Baseline in Body Weight Z-Score at EOT1.637 ± 2.8839
PrimaryChange From Baseline in Height Z-Score at EOT

A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a height for age Z-score below -2 indicates stunted.

Time frame:
Baseline, EOT (up to 47.3-51.3 weeks)
Reported as:
Mean · Z score
Change From Baseline in Height Z-Score at EOT
Z scoreTeduglutide
Change From Baseline in Height Z-Score at EOT0.590 ± 1.9949
PrimaryChange From Baseline in Head Circumference Z-Score at EOT

A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to the Food and Nutrition Technical Assistance (FANTA) Guide to Anthropometry used for assessment of this outcome measure, a head circumference for age Z-score below -2 indicates small head circumference.

Time frame:
Baseline, EOT (up to 47.3-51.3 weeks)
Reported as:
Mean · Z score
Change From Baseline in Head Circumference Z-Score at EOT
Z scoreTeduglutide
Change From Baseline in Head Circumference Z-Score at EOT1.130 ± 0.4101
PrimaryChange From Baseline in Weight-for-Length Z-Score at EOT

A Z-score is the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). According to WHO Child Growth Standards used for assessment of this outcome measure, a weight for length Z-score below -2 indicates wasted (recent and severe weight loss).

Time frame:
Baseline, EOT (up to 47.3-51.3 weeks)
Reported as:
Mean · Z score
Change From Baseline in Weight-for-Length Z-Score at EOT
Z scoreTeduglutide
Change From Baseline in Weight-for-Length Z-Score at EOT4.240 ± NA
PrimaryNumber of Participants With Any Laboratory Safety Finding Reported as an Adverse Event

Laboratory safety parameters included biochemistry, hematology, and urinalysis.

Time frame:
From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Reported as:
Count of participants · Participants
Number of Participants With Any Laboratory Safety Finding Reported as an Adverse Event
ParticipantsTeduglutide
Number of Participants With Any Laboratory Safety Finding Reported as an Adverse Event1
PrimaryNumber of Participants With a Change in Urine Output Reported as an Adverse Event

Urine and stool output was recorded and calculated in the output diary over a 48-hour period of parenteral support (PS) and enteral nutrition (EN) stability before every site visit and within 1 week of implementing a change in the PS prescription.

Time frame:
From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Reported as:
Count of participants · Participants
Number of Participants With a Change in Urine Output Reported as an Adverse Event
ParticipantsTeduglutide
Number of Participants With a Change in Urine Output Reported as an Adverse Event1
PrimaryNumber of Participants With a Change in Stool Output Reported as an Adverse Event

Urine and stool output was recorded and calculated in the output diary over a 48-hour period of PS and EN stability before every site visit and within 1 week of implementing a change in the PS prescription.

Time frame:
From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks])
Reported as:
Count of participants · Participants
Number of Participants With a Change in Stool Output Reported as an Adverse Event
ParticipantsTeduglutide
Number of Participants With a Change in Stool Output Reported as an Adverse Event0
SecondaryChange From Baseline in PS Volume

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period. An end of treatment (EOT) was defined as the last determination of endpoint of the last cycle.

Time frame:
Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2: Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]
Reported as:
Mean · milliliters per kilograms (mL/kg)/day
Change From Baseline in PS Volume
milliliters per kilograms (mL/kg)/dayTeduglutide
Cycle 1, Week 13.13 ± 10.041
Cycle 1, Week 27.82 ± 19.334
Cycle 1, Week 4-1.31 ± 6.491
Cycle 1, Week 810.27 ± 13.788
Cycle 1, Week 125.83 ± 15.979
Cycle 1, Week 161.89 ± 16.386
Cycle 1, Week 201.82 ± 6.673
Cycle 1, Week 240.66 ± 9.511
Cycle 1, EOT0.66 ± 9.511
Cycle 2, Week 0-0.07 ± 12.808
Cycle 2 Week 10.11 ± 15.080
Cycle 2, Week 2-2.32 ± 13.465
Cycle 2, Week 4-0.71 ± 12.202
Cycle 2, Week 8-4.81 ± 13.214
Cycle 2, Week 12-8.42 ± 11.909
Cycle 2, Week 16-10.14 ± 10.452
Cycle 2, Week 20-8.20 ± 0.509
Cycle 2, Week 24-9.28 ± 2.092
Cycle 2, EOT-9.11 ± 1.508
Cycle 3, Week 0-12.86 ± NA
Cycle 3, Week 1-13.67 ± NA
Cycle 3, Week 2-5.04 ± NA
Cycle 3, EOT-5.04 ± NA
Overall EOT-10.99 ± 27.093
SecondaryPercent Change From Baseline in PS Volume

Percent change from baseline in PS volume was calculated as follows; (PS volume at each point \[Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT\] - PS volume at baseline)/ PS volume at baseline \*100 (percent). PS (parenteral nutrition or intravenous fluids) was to be considered for managing nutritional support in terms of volume and calories during the treatment period. An EOT was defined as the last determination of endpoint of the last cycle.

Time frame:
Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]
Reported as:
Mean · percent change
Percent Change From Baseline in PS Volume
percent changeTeduglutide
Cycle 1, Week 14.82 ± 13.391
Cycle 1, Week 211.27 ± 26.175
Cycle 1, Week 4-1.51 ± 8.881
Cycle 1, Week 813.48 ± 19.471
Cycle 1, Week 126.97 ± 22.006
Cycle 1, Week 161.61 ± 22.136
Cycle 1, Week 202.94 ± 8.794
Cycle 1, Week 241.24 ± 12.938
Cycle 1, EOT1.24 ± 12.938
Cycle 2, Week 00.07 ± 17.520
Cycle 2, Week 10.26 ± 20.634
Cycle 2, Week 2-2.81 ± 18.432
Cycle 2, Week 4-0.62 ± 16.671
Cycle 2, Week 8-6.00 ± 18.175
Cycle 2, Week 12-10.21 ± 16.645
Cycle 2, Week 16-13.03 ± 14.937
Cycle 2, Week 20-9.73 ± 3.073
Cycle 2, Week 24-10.50 ± 6.059
Cycle 2, EOT-10.98 ± 4.363
Cycle 3, Week 0-17.69 ± NA
Cycle 3, Week 1-18.79 ± NA
Cycle 3, Week 2-6.93 ± NA
Cycle 3, EOT-6.93 ± NA
Overall EOT-13.13 ± 37.259
SecondaryNumber of Participants Who Demonstrate at Least 20 Percent (%) Reduction From Baseline in PS Volume

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period. An EOT was defined as the last determination of endpoint of the last cycle.

Time frame:
Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]
Reported as:
Count of participants · Participants
Number of Participants Who Demonstrate at Least 20 Percent (%) Reduction From Baseline in PS Volume
ParticipantsTeduglutide
Cycle 1, Week 10
Cycle 1, Week 20
Cycle 1, Week 40
Cycle 1, Week 80
Cycle 1, Week 120
Cycle 1, Week 161
Cycle 1, Week 200
Cycle 1, Week 240
Cycle 1, EOT0
Cycle 2, Week 00
Cycle 2, Week 11
Cycle 2, Week 21
Cycle 2, Week 40
Cycle 2, Week 81
Cycle 2, Week 121
Cycle 2, Week 161
Cycle 2, Week 200
Cycle 2, Week 240
Cycle 2, EOT0
Cycle 3, Week 00
Cycle 3, Week 10
Cycle 3, Week 20
Cycle 3, EOT0
Overall EOT1
SecondaryNumber of Participants Who Achieved Enteral Autonomy

Achieving enteral autonomy is defined as complete weaning off PS. PS (parenteral nutrition or intravenous fluids) was to be considered for managing nutritional support in terms of volume and calories during the treatment period.

Time frame:
Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT and overall EOT (for up to 47.3-51.3 weeks) [cycle length=28 weeks]
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Enteral Autonomy
ParticipantsTeduglutide
Cycle 1, Week 10
Cycle 1, Week 20
Cycle 1, Week 40
Cycle 1, Week 80
Cycle 1, Week 120
Cycle 1, Week 160
Cycle 1, Week 200
Cycle 1, Week 240
Cycle 1, EOT0
Cycle 2, Week 00
Cycle 2, Week 10
Cycle 2, Week 20
Cycle 2, Week 40
Cycle 2, Week 80
Cycle 2, Week 120
Cycle 2, Week 160
Cycle 2, Week 200
Cycle 2, Week 240
Cycle 2, EOT0
Cycle 3, Week 00
Cycle 3, Week 10
Cycle 3, Week 20
Cycle 3, EOT0
Overall EOT0
SecondaryChange From Baseline in Number of Days Per Week of PS Usage at EOT

PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume and calories during the treatment period.

Time frame:
Baseline, Cycle 1 = Week 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 2 = Week 0, 1, 2, 4, 8, 12, 16, 20, 24, and EOT, Cycle 3 = Week 0, 1, 2, and EOT, and overall EOT (for 47.3-51.3 weeks) [cycle length=28 weeks]
Reported as:
Mean · days per week
Change From Baseline in Number of Days Per Week of PS Usage at EOT
days per weekTeduglutide
Cycle 1, Week 10.0 ± 0.00
Cycle 1, Week 20.0 ± 0.00
Cycle 1, Week 40.0 ± 0.00
Cycle 1, Week 80.0 ± 0.00
Cycle 1, Week 120.0 ± 0.00
Cycle 1, Week 160.0 ± 0.00
Cycle 1, Week 200.0 ± 0.00
Cycle 1, Week 240.0 ± 0.00
Cycle 1, EOT0.0 ± 0.00
Cycle 2, Week 00.0 ± 0.00
Cycle 2, Week 10.0 ± 0.00
Cycle 2, Week 20.0 ± 0.00
Cycle 2, Week 40.0 ± 0.00
Cycle 2, Week 80.0 ± 0.00
Cycle 2, Week 120.0 ± 0.00
Cycle 2, Week 160.0 ± 0.00
Cycle 2, Week 200.0 ± 0.00
Cycle 2, Week 240.0 ± 0.00
Cycle 2, EOT0.0 ± 0.00
Cycle 3, Week 00.0 ± 0.00
Cycle 3, Week 10.0 ± NA
Cycle 3, Week 20.0 ± NA
Cycle 3, EOT0.0 ± NA
Overall EOT0.0 ± 0.00

Adverse events

Collected over From first dose of study drug until follow-up visit (4 weeks after EOT/ET [up to 47.3-51.3 weeks]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teduglutide0/3 (0%)3/3 (100%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventTeduglutide
Device related infectionInfections and infestations2/3
BacteraemiaInfections and infestations1/3
Catheter site pruritusGeneral disorders1/3
Device breakageProduct Issues1/3
Vascular device occlusionGeneral disorders1/3
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTeduglutide
COVID-19Infections and infestations2/3
EnterocolitisGastrointestinal disorders2/3
Respiratory syncytial virus infectionInfections and infestations2/3
Blood iron increasedInvestigations1/3
Catheter site rashGeneral disorders1/3
Lactic acidosisMetabolism and nutrition disorders1/3
Liver disorderHepatobiliary disorders1/3
OliguriaRenal and urinary disorders1/3
Parainfluenzae virus infectionInfections and infestations1/3
Skin candidaInfections and infestations1/3

Baseline characteristics

Safety Analysis Set included all participants who received at least 1 dose of study teduglutide.

Age, Categorical
Age, Categorical(Participants)Teduglutide
<=18 years3
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Teduglutide
Female2
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Teduglutide
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Teduglutide
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Teduglutide
Japan3
Height for Age Z-Score at Baseline
Height for Age Z-Score at Baseline(Z score)Teduglutide
Mean-3.060 ± 1.1601
Weight for Age Z-Score at Baseline
Weight for Age Z-Score at Baseline(Z score)Teduglutide
Mean-3.017 ± 1.8048
08

Study locations

6 sites
  • University of Tsukuba Hospital
    Tsukuba, Ibaraki, Japan
  • Tohoku University Hospital
    Sendai, Miyagi, Japan
  • Showa University Hospital
    Shinagawa-ku, Tokyo, Japan
  • Akita University Hospital
    Akita, Japan
  • Kyushu University Hospital
    Fukuoka, Japan
  • Kagoshiha University Hospital
    Kagoshima, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be reidentified (due to the limited number of study participants/study sites).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Sep 2023, 20 months.

Results were first posted in May 2024, 7 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 20 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2021
First posted
Aug 30, 2021
StartActual
Jan 4, 2022
Primary completionActual
Sep 27, 2023
CompletionActual
Sep 27, 2023
Results first posted
May 16, 2024
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05027308
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Jan 4, 2022
Primary completion
Sep 27, 2023
Completion
Sep 27, 2023
Results posted
May 16, 2024
Last update
May 16, 2024

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion